Should the board continue patient testing and retail expansion, pause for independent validation, ring-fence a narrowly validated menu, or begin a partner-controlled strategic review?
Clinical laboratory validation and retail-rollout decision
Decision time
October 28, 2015
Knowledge cutoff
October 28, 2015
Recommended path
The option value of a controlled pause exceeds the risk of continuing patient-facing testing without full-menu evidence; any surviving assay can be relaunched after independent validation, while financial valuation must abstain.
Confidence
High
What happened
At the cutoff, Theranos publicly rebutted accuracy criticism and remained in a continuing posture while Walgreens had reportedly paused expansion; the evidence set contains no verified cutoff board resolution.
The frozen recommendation to pause patient testing and expansion for independent assay-by-assay and end-to-end validation was process-sound. It addressed asymmetric patient harm and preserved relaunch option value without presuming that all tests were inaccurate, that inspectional observations were final findings, or that later misconduct had already been proved.
Pause the unsupported workflows, preserve records and specimens, and allow patient use only after independent blinded validation and quality-system gates clear for every offered combination.
Assay- and workflow-specific gates prevent narrow evidence from being extrapolated across heterogeneous tests and stop unresolved quality failures from propagating through patients, partners, regulators, and capital providers.
Candidatemoderate confidence
rule.preserve-legal-and-measurement-status
Preserve each proposition's legal and epistemic status and prohibit additive financial or causal conclusions until an independently reconciled bridge proves compatibility and non-overlap.
Status and measurement separation prevents allegations from becoming findings, defendant-specific verdicts from becoming enterprise-wide conclusions, and heterogeneous monetary records from becoming a fabricated loss estimate.